Displaying 58 (all) recruiting clinical trials.
-
A Phase 1 Study of NKX019 a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy in Subjects with Lupus Nephritis
The purpose of this study is to investigate NKX019, which is made from one type of white blood cell called a natural killer (NK) cell ...Phase
Interventional
-
Phase
Interventional
-
A Phase 1a/1b Trial of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors
This study is testing the tolerability, effectiveness, and potential for few side effects of the drug LY3962673 in patients with advanced solid tumors that have ...
Phase
Interventional
-
<strong>Adolescents:</strong> A Prospective Single Arm Open Label Trial to Confirm Safety and Effectiveness of Prism as an Adjunct to Standard of Care in Adolescents with Post-Traumatic Stress Disorder (PTSD)
The purpose of this research study is to is to establish if the FDA-approved Prism device, currently used for treating adult PTSD patients can also ...Phase
Interventional
-
Immunologic Basis of Food Protein-Induced Enterocolitis Syndrome (INFINITY)
The purpose of this study is to find out if a new low-dose oral food challenge (OFC) over 7 days can accurately diagnose food protein-induced ...Phase
Interventional
-
A Phase 1 Study of the Polymerase Theta Inhibitor Novobiocin in BRCA-Mutant and Other DNA Damage Repair-Deficient Solid Tumors
To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of novobiocin administered on a 5-days on/2-days off schedule in patients ...Phase
Interventional
-
A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
This study is being done to determine if we can combine lenalidomide with full doses of EPOCH chemotherapy for your ATLL, and to define the ...Phase
Interventional
-
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics and Anti-tumor Efficacy of DZD6008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation (TIAN-SHAN1)
This is a phase 1 study testing a new medicine called DZD6008 (an EGFR inhibitor) in patients with lung cancer with EGFR mutation.
This study ...
Phase
Interventional
